Literature DB >> 19931269

Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation.

Roberto Cirombella1, Giuseppe Montrone, Antonella Stoppacciaro, Simona Giglio, Stefano Volinia, Paolo Graziano, Kay Huebner, Andrea Vecchione.   

Abstract

Loss of heterozygosity at the FHIT locus is coincident with activation of DNA damage response checkpoint proteins; thus damage at fragile loci may trigger checkpoint activation. We examined preneoplastic lesions adjacent to non-small cell lung carcinomas for alterations to expression of Fhit and activated checkpoint proteins. Expression scores were analyzed for pair-wise associations and correlations among proteins and type of lesion. Hyperplastic and dysplastic lesions were positive for nuclear gammaH2AX expression; 12/20 dysplastic lesions were negative for Fhit expression. Fhit positive lesions showed expression of most checkpoint proteins examined, while Fhit negative lesions showed absence of expression of Chk1 and phosphoChk1. The results show that loss of expression of Fhit is significantly directly correlated with absence of activated Chk1 in dysplasia, and suggest a connection between loss of Fhit and modulation of checkpoint activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19931269      PMCID: PMC2849884          DOI: 10.1016/j.canlet.2009.10.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  32 in total

Review 1.  Molecular and genetic aspects of lung cancer.

Authors:  W N Rom; J G Hay; T C Lee; Y Jiang; K M Tchou-Wong
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

Review 2.  Screening for lung cancer.

Authors:  E F Patz; P C Goodman; G Bepler
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis.

Authors:  A Kitamura; K Yashima; E Okamoto; H Andachi; A Hosoda; Y Kishimoto; G Shiota; H Ito; N Kaibara; H Kawasaki
Journal:  Oncology       Date:  2001       Impact factor: 2.935

4.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

Authors:  Vassilis G Gorgoulis; Leandros-Vassilios F Vassiliou; Panagiotis Karakaidos; Panayotis Zacharatos; Athanassios Kotsinas; Triantafillos Liloglou; Monica Venere; Richard A Ditullio; Nikolaos G Kastrinakis; Brynn Levy; Dimitris Kletsas; Akihiro Yoneta; Meenhard Herlyn; Christos Kittas; Thanos D Halazonetis
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

5.  Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression.

Authors:  M Indinnimeo; E Giarnieri; A Stazi; C Cicchini; S Brozzetti; C Valli; I Carreca; A Vecchione
Journal:  Cancer Lett       Date:  1997-01-01       Impact factor: 8.679

6.  Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation.

Authors:  J Y Ahn; J K Schwarz; H Piwnica-Worms; C E Canman
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

7.  Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints.

Authors:  W A Cliby; C J Roberts; K A Cimprich; C M Stringer; J R Lamb; S L Schreiber; S H Friend
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

8.  The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.

Authors:  Gulnur Guler; Aysegul Uner; Nilufer Guler; Shuang-Yin Han; Dimitrios Iliopoulos; Walter W Hauck; Peter McCue; Kay Huebner
Journal:  Cancer       Date:  2004-04-15       Impact factor: 6.860

9.  Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer.

Authors:  David Butler; Claire Collins; Mohamed Mabruk; Mary B Leader; Elaine W Kay
Journal:  Gynecol Oncol       Date:  2002-08       Impact factor: 5.482

10.  ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation.

Authors:  Ester M Hammond; Mary Jo Dorie; Amato J Giaccia
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

View more
  5 in total

1.  Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features.

Authors:  Gulnur Guler; Cigdem Himmetoglu; Rafael E Jimenez; Susan M Geyer; Wenle P Wang; Stefan Costinean; Robert T Pilarski; Carl Morrison; Dinc Suren; Jianhua Liu; Jingchun Chen; Jyoti Kamal; Charles L Shapiro; Kay Huebner
Journal:  Breast Cancer Res Treat       Date:  2010-11-11       Impact factor: 4.872

2.  microRNA-based cancer cell reprogramming technology.

Authors:  Shimpei Nishikawa; Hideshi Ishii; Naotsugu Haraguchi; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Miyuki Ozaki; Dyah Laksmi Dewi; Daisuke Sakai; Taroh Satoh; Hiroaki Nagano; Yuichiro Doki; Masaki Mori
Journal:  Exp Ther Med       Date:  2012-04-23       Impact factor: 2.447

3.  FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.

Authors:  Catherine E Waters; Joshua C Saldivar; Zaynab A Amin; Morgan S Schrock; Kay Huebner
Journal:  Oncotarget       Date:  2015-02-20

Review 4.  Sensing Bacterial-Induced DNA Damaging Effects via Natural Killer Group 2 Member D Immune Receptor: From Dysbiosis to Autoimmunity and Carcinogenesis.

Authors:  J Luis Espinoza; Mika Minami
Journal:  Front Immunol       Date:  2018-01-25       Impact factor: 7.561

5.  FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.

Authors:  Svenja Dannewitz Prosseda; Xuefei Tian; Kazuya Kuramoto; Mario Boehm; Deepti Sudheendra; Kazuya Miyagawa; Fan Zhang; David Solow-Cordero; Joshua C Saldivar; Eric D Austin; James E Loyd; Lisa Wheeler; Adam Andruska; Michele Donato; Lingli Wang; Kay Huebner; Ross J Metzger; Purvesh Khatri; Edda Spiekerkoetter
Journal:  Am J Respir Crit Care Med       Date:  2019-01-01       Impact factor: 30.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.